What is Ostia Sciences?
Ostia Sciences Inc. operates at the intersection of synthetic biology and clinical pharmacology, specializing in the development of beneficial microbes designed to combat infectious diseases and bolster immune function. The company has garnered significant industry attention for its pioneering work on Salivaricin 10, recognized as the world's first phosphorylated antibiotic. By leveraging a sophisticated research platform, Ostia Sciences identifies and characterizes probiotics with distinct drug-like properties, effectively bridging the gap between nutritional supplements and pharmaceutical-grade interventions. This microbiome-centric approach positions the startup as a critical player in the evolving landscape of preventative healthcare and targeted therapeutic innovation.
How much funding has Ostia Sciences raised?
Ostia Sciences has raised a total of $1M across 1 funding round:
Seed
$1M
Seed (2025): $1M, investors not publicly disclosed
Key Investors in Ostia Sciences
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Ostia Sciences?
With the recent influx of capital, Ostia Sciences is expected to scale its clinical trial operations and expand its proprietary research infrastructure. The strategic focus will likely shift toward navigating regulatory pathways for its lead candidates while deepening its intellectual property portfolio in the microbiome space. As the company transitions from early-stage development to more advanced clinical validation, the primary objective remains the commercialization of its unique antibiotic alternatives. Investors and industry stakeholders will be closely monitoring the firm's ability to translate its laboratory successes into scalable, market-ready healthcare solutions that address the growing global challenge of antibiotic resistance.
See full Ostia Sciences company page
